Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disorder in which up to 70% of the patients have central nervous system (CNS) abnormalities. 1 It is well accepted that the occurrence of CNS alterations in lupus is associated with poor outcome and reduced survival. The wide range of physiopathogenic mechanisms and manifestations of CNS disease in SLE requires constant reappraisal of the knowledge in order to provide better patient care and improve prognosis. These facts show the importance of this collection of state-of-the-art articles specially prepared for the journal Lupus. We were honored to be invited by Professor Hughes to take over this task, and invited investigators that are experts in the field to write articles addressing different important aspects of the CNS involvement in lupus. The areas covered by this edition of 15 papers include: experimental lupus (2 articles), CNS involvement in childhood-onset SLE (2 articles), imaging (2 articles), autoantibodies and soluble biomarkers mainly anti-ribosomal P antibodies (3 articles), infection (1 article), clinical management and tools (2 articles), stroke and antiphospholipid syndrome (APS) (1 article) and pregnancy and offspring outcome (2 articles).
The first article of this issue is an interesting and didactical review of the role of anti-ribosomal P antibodies in the context of neurological manifestations in lupus written by the well respected authors (Bonfa and Elkon) that first described the anti-ribosomal P antibody's relationship to lupus psychosis in 1986.
The second article is from the Bonfa group and reports the findings on an elegant experimental autoimmunity model (Gaburo Jr. et al.) . They demonstrate the role of anti-ribosomal P antibodies in inducing CNS electrophysiological dysfunction in rats. Following this is a paper by the Shoenfeld group, that has generated many of the most outstanding data in this field, that reviews the CNS lupus pathogenic mechanisms from experimental animal models translated into human disease (Pikman et al.). These findings have opened new avenues in understanding the mechanisms and introduced novel treatment approaches.
There are two studies involving the pediatric population that have been included in this issue. In this context, previous studies demonstrated that higher sera S100b protein levels have been reported to reflect brain injury and increased permeability of the blood-brain barrier. In addition, higher sera S100b protein levels were observed in adults with neuropsychiatric SLE (NPSLE). The study by Lapa and colleagues published here, evaluated, for the first time, the S100b protein levels in children with SLE and its association with CNS lupus (Lapa et al.) . In the other pediatric study, the classical anti-ribosomal P antibody was studied in a large Brazilian multicenter cohort of 228 childhood-onset SLE patients; the authors report an association with mood disorders and a novel association with hemolytic anemia (Valo˜es et al.) .
Regarding the clinical aspects of NPSLE, the diagnostic challenges of decisive differentiation with the various forms of infections was thoroughly reviewed by Ribeiro and Signorelli. In fact, opportunistic infections can cause manifestations that resemble neurological SLE manifestations and they also can trigger lupus flares. Since the manifestations can overlap, CNS infections as differential diagnosis in NPSLE may be difficult, leading to delayed diagnosis and are important for treatment decision making (Ribeiro and Signorelli). John Hanly contributed with an impeccable article about the importance of the proper characterization and attribution to SLE and non-SLE NP events, involving clinical appraisal, selection and Correspondence to: RA Levy, Rheumatology Division, Hospital Universita´rio Pedro Ernesto Universidade do Estado do Rio de Janeiro Blvd 28 de Setembro 77, sala 333 Vila Isabel, 20551-030, Rio de Janeiro, RJ, Brazil. Email: roger.a.levy@gmail.com interpretation of laboratory and imaging findings (Hanly). There is a major effort to improve the understanding of the immunopathogenetic mechanisms and identifying the clinical outcomes of NPSLE to develop well designed clinical trials. Within this concept, Clark and colleagues performed interesting critical analysis of the available tools that can be used to evaluate NPSLE (Clark et al). The authors led by Anisur Rahman, called the attention for the fact that the NP manifestations in SLE are not always linked to disease activity, and that there is no single biomarker or imaging test to differentiate CNS involvement due to lupus or infections, although novel imaging methods are under investigation.
The study of CNS imaging is crucial for the progress in diagnosis and treatment care. In this way, the readers will be pleased to read interesting articles from Appenzeller's (Postal et al.) and Cervera's (Sarbu et al.) groups. With the magnetic resonance imaging (MRI) technique, Postal and colleagues showed that structural and functional abnormalities may be found in 19-70% of SLE patients. The authors review several different MRI techniques, including the advanced MRI methods recently introduced and under investigation to determine with greater precision the CNS involvement in SLE. Sarbu and colleagues assessed whether clinical and patient's reported outcomes are associated with a different pathophysiologic origin of NP events presenting in SLE. As a result, the authors observed changes between scores at paired visits of all domain scores, mental component summary (SF-36 MCS) and physical component summary (SF-36 PCS) scores were retrospectively calculated. The results are impressive (Sarbu et al.) .
Ophthalmological manifestation seen in lupus and their relationship with neurological manifestations were addressed by de Andrade and colleagues. In fact, ophthalmologic disease in SLE has been associated with neurologic flares, antiphospholipid antibodies, and mainly increased mortality (de Andrade et al.) . In addition to that, strokes linked to antiphospholipid syndrome, a disease highly linked to lupus, was the theme of de Amorim's article, an elegant review that brings up the discussion on risk factors, diagnostic and treatment of this mostly thrombotic vascular condition (de Amorim et al.) .
De Jesus and colleagues (de Jesus et al.) assessed gestational results of 26 pregnancies in NPSLE patients, followed at the reference center in Rio de Janeiro, Brazil. Of the 26 pregnancies, 3 had active NPSLE at conception, and only 1 remained active throughout pregnancy. The authors found that patients with NPSLE had more prematurity and preeclampsia compared with patients without past NP disease, although this finding could be biased by concomitant renal disease, which are clearly related to worse pregnancy outcomes.
From the Leiden cohort, 232 NP events presenting in 131 SLE patients were evaluated in terms of clinical and quality of life outcomes, and compared according to their probable underlying pathophysiology (Magro-Checa et al.) . The patients were separated as (a) not related to NPSLE (28.6%); and if NPSLE, as (b) inflammatory (51.6%) or (c) ischemic (15.8%). The authors found that patients that had inflammatory NPSLE events had better clinical outcome and a significant improvement in SF-36 MCS compared with those with past ischemic NPSLE or NP events not related to SLE.
The last article of this special edition is from Tincani's group (Nalli et al.) . They evaluated the long-term neuro-developmental outcome in 40 children with a median age of around 7 years old, that were born to mothers with SLE and/or APS that had detectable IgG anti-phospholipid antibodies during the third trimester of pregnancy. By a series of neurologic, cognitive, learning abilities and emotional testing applied to the children, according to the mother's questionnaire, 15 children (37.5%) had an increased risk of behavioral problems, epilepsy, sleep disorders and learning disabilities were more commonly reported than in the general population. These findings stress the importance of long-term follow up of children born to mothers with antiphospholipid antibodies.
